Mercy BioAnalytics has received FDA approval for its Evident Ovarian Cancer Screening Test, enabling a pivotal clinical study to improve early detection for women at average risk.

Mercy BioAnalytics announces presentations at ASCO 2026 showcasing innovative blood tests for early lung cancer detection, utilizing NLST biospecimens to validate their effectiveness.

Mercy BioAnalytics names Darrin Crisitello as Chief Commercial Officer. With over 20 years in the commercial sector, he aims to enhance cancer detection.

Mercy BioAnalytics has appointed Ellen Snow as Chief Financial Officer. She brings over 20 years of experience to aid the company in their mission of early cancer detection.

A new study showcases the effectiveness of the Mercy Halo blood test in early lung cancer detection, potentially enhancing screening strategies for at-risk individuals.

Mercy BioAnalytics has published a study showcasing a blood test that detects ovarian cancer with unprecedented effectiveness, potentially changing detection methods.

Mercy BioAnalytics has successfully closed a $59 million Series B financing round aimed at advancing its early cancer detection programs, marking a significant milestone in oncology diagnostics.

Mercy BioAnalytics has appointed Dr. Prasanth Reddy as Chief Medical Officer. His expertise in oncology will help enhance early cancer detection efforts.